Highlights

  • ImpediMed has successfully completed its Share Purchase Plan (SPP), raising AUD 2.1 million.
  • The SPP attracted applications totalling AUD 3.5 million, exceeding the original AUD 2.0 million target.
  • The Capital raising follows the company's previously completed AUD 13.2 million institutional Placement.
  • The Board resolved to accept an additional AUD 0.1 million in oversubscriptions above the initial target.
  • Approximately 300 million SPP shares are expected to be issued at AUD 0.007 per share, subject to Shareholder approval.
  • Participants will receive one Attaching Option and one Follow-on Option for each SPP share issued.

ImpediMed Limited (ASX:IPD) has announced the successful completion of its Share Purchase Plan (SPP), with shareholder Demand exceeding the original target amount. The company confirmed that the offer attracted applications worth AUD 3.5 million, prompting the Board to accept additional oversubscriptions and increase the total amount raised under the plan to AUD 2.1 million.

The capital raising forms part of a broader funding initiative that follows a previously completed AUD 13.2 million institutional placement. According to the company, the strong level of participation reflects continued shareholder engagement as ImpediMed progresses its strategic priorities and growth initiatives.

ImpediMed shares were trading flat at AUD 0.0060 during the afternoon session on 10 June 2026. Despite today's unchanged performance, the stock remains down 80.00% over the past 12 months.

About ImpediMed

ImpediMed is a medical technology company headquartered in Sydney, Australia, with additional operations in the United States and Europe. The company specialises in bioimpedance spectroscopy (BIS) technology, which is used to generate physiological data that can assist healthcare professionals in monitoring and managing patient health.

Its flagship product is the SOZO® Digital Health Platform, which has received regulatory clearances and approvals across multiple jurisdictions, including clearance from the United States Food and Drug Administration (FDA), CE marking in Europe and listing on the Australian Register of Therapeutic Goods (ARTG).

The platform supports several clinical applications, including lymphoedema assessment, heart failure management and protein calorie malnutrition monitoring. ImpediMed also markets its proprietary L-Dex® technology, which uses bioimpedance spectroscopy for the clinical assessment of lymphoedema.

The company operates a software-as-a-service (SaaS)-based Business model and continues to focus on expanding adoption of its digital health technologies across global healthcare markets.

Share Purchase Plan Attracts Strong Investor Participation

The latest announcement centres on the successful completion of the Share Purchase Plan, which closed on 5 June 2026.

The SPP provided eligible shareholders in Australia and New Zealand with the opportunity to purchase additional ImpediMed shares without brokerage fees, commissions or other Transaction Costs.

Eligible investors were able to apply for up to AUD 100,000 worth of new fully paid ordinary shares under the offer.

According to the company, applications received under the plan totalled AUD 3.5 million, significantly exceeding the original fundraising target of AUD 2.0 million.

The level of demand resulted in the offer being oversubscribed, prompting the Board to consider the acceptance of additional subscriptions beyond the initial target.

The company noted that the outcome demonstrated continued shareholder participation in the capital raising process.

Board Accepts Additional Oversubscriptions

As part of the Share Purchase Plan framework, ImpediMed previously disclosed that it retained discretion to accept additional subscriptions above the original target amount.

Following the close of the offer, the Board resolved to increase the amount raised by accepting up to an additional AUD 0.1 million in oversubscriptions.

As a result, the total amount raised under the SPP will increase from the original AUD 2.0 million target to AUD 2.1 million.

The company stated that approximately AUD 1.4 million in oversubscription applications were received.

Because demand exceeded the amount ultimately accepted, a scale-back process will be implemented.

ImpediMed confirmed that the scale-back will be applied on a pro-rata basis.

This approach is intended to allocate shares among participating investors while remaining within the approved fundraising limit.

Capital Raising Builds on Institutional Placement

The Share Purchase Plan follows ImpediMed's previously completed institutional placement, which raised AUD 13.2 million.

Combined, the placement and SPP form part of the company's broader capital management activities.

While the announcement did not provide a detailed breakdown of planned use of proceeds, the successful completion of both funding initiatives increases the capital available to support the company's operational and strategic priorities.

The latest fundraising outcome also provides an indication of shareholder engagement following the institutional placement process.

Management highlighted the positive response from investors and acknowledged the support received through participation in the offer.

Issue Price Set at Discount to VWAP

The issue price for shares under the Share Purchase Plan was determined in accordance with the terms outlined in the company's prospectus.

ImpediMed confirmed that SPP shares will be issued at AUD 0.007 per share.

According to the company, this represented a 2.5% discount to the five-day Volume weighted average price (VWAP) of ImpediMed shares traded on the ASX up to and including the closing date of the offer.

Based on the final amount accepted under the SPP, approximately 300 million new shares are expected to be issued.

The company indicated that these shares will be issued following shareholder approval at the upcoming Extraordinary General Meeting.

Additional Options Included for Participants

In addition to receiving new shares, participants in the Share Purchase Plan will also receive options attached to their Investment.

For every SPP share issued, investors will receive one Attaching Option.

Participants will also receive one Follow-on Option for each share issued under the plan.

The company explained that the Follow-on Option may be exercised following the valid exercise of the first Attaching Option.

These securities form part of the overall fundraising structure and are intended to accompany shares issued through both the Share Purchase Plan and the placement.

Further details regarding the terms of the options are outlined within the company's prospectus documentation.

Shareholder Approval Required Before Issue

The issue of SPP shares, associated options and Tranche 2 of the institutional placement remains subject to shareholder approval.

ImpediMed has scheduled an Extraordinary General Meeting (EGM) for 11 June 2026.

At the meeting, shareholders will be asked to consider resolutions relating to the capital raising and associated securities.

If approval is obtained, the company intends to proceed with the issue of shares and options under both the placement and Share Purchase Plan.

The company also stated that it will apply for Quotation of all new shares and options issued as part of the fundraising process.

This approval process represents the final step before the securities can be formally issued.

Expected Timetable for Share Issue

ImpediMed provided a timetable outlining the expected next stages of the Share Purchase Plan.

Subject to shareholder approval, the company expects the SPP shares, Attaching Options and Follow-on Options to be issued on 15 June 2026.

Trading of the new securities on the ASX is expected to commence on 16 June 2026.

Holding statements for successful applicants are also expected to be dispatched on 16 June 2026.

These dates remain subject to completion of the approval process and any necessary regulatory requirements.

The timetable provides participating shareholders with visibility regarding the expected allocation and commencement of trading.

Board Highlights Shareholder Support

ImpediMed Chair Christine Emmanuel-Donnelly acknowledged the level of participation received under the offer.

The company stated that the strong response to the Share Purchase Plan reflected ongoing support from shareholders.

Management thanked investors for their participation and commitment to the company, noting that the fundraising outcome provides support for the company's next stage of development.

The Board also emphasised its appreciation for shareholders who elected to participate in the offer despite demand exceeding the original fundraising target.

The positive response resulted in the company increasing the amount raised under the SPP while still applying a scale-back mechanism due to oversubscription levels.

Digital Health Platform Remains Core Focus

Beyond the capital raising, ImpediMed continues to focus on expanding adoption of its SOZO Digital Health Platform.

The platform is used across several clinical applications and has received regulatory clearances in multiple jurisdictions.

The company highlighted that bioimpedance spectroscopy remains referenced within the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Survivorship as an objective screening tool for at-risk cancer patients showing early signs of lymphoedema.

ImpediMed states that it remains the only company offering FDA-cleared bioimpedance spectroscopy technology for clinical lymphoedema assessment.

The company continues to pursue opportunities associated with its SaaS-based healthcare model and digital health platform expansion.

What This Means for Investors

ImpediMed's latest announcement focuses on the successful completion of its Share Purchase Plan, which attracted demand above the original fundraising target. Applications reached AUD 3.5 million, leading the Board to increase the amount raised under the offer to AUD 2.1 million while implementing a pro-rata scale-back.

The fundraising follows a previously completed AUD 13.2 million institutional placement and remains subject to shareholder approval at the company's Extraordinary General Meeting scheduled for 11 June 2026. Investors are likely to monitor the outcome of the meeting and the subsequent issue of shares and options under the capital raising program.